Search Results
Apr 14, 2026, 08:00 ET Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules
calibration standards and supports faster results and more confident comparisons, streamlining work across biosimilarity studies, antibody-drug conjugate (ADC) characterization, and viral vector analytics. As these modalities and other advanced therapeutics move into late-stage development and quality control,
More news about: Waters Corporation
Apr 14, 2026, 08:00 ET Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules
calibration standards and supports faster results and more confident comparisons, streamlining work across biosimilarity studies, antibody-drug conjugate (ADC) characterization, and viral vector analytics. As these modalities and other advanced therapeutics move into late-stage development and quality control,
More news about: Waters Corporation
Apr 14, 2026, 06:00 ET Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline
will be used to support Adcendo through multiple upcoming key clinical milestones from the Company's first- and best-in-class ADC pipeline, including the ADCE-T02 (Tissue Factor ADC) Phase I Tiffany-01 Cohort expansion study in multiple high unmet need tumor indications, the ADCE-D01 (uPARAP) ADCElerate1
More news about: Adcendo
Apr 14, 2026, 06:00 ET Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline
will be used to support Adcendo through multiple upcoming key clinical milestones from the Company's first- and best-in-class ADC pipeline, including the ADCE-T02 (Tissue Factor ADC) Phase I Tiffany-01 Cohort expansion study in multiple high unmet need tumor indications, the ADCE-D01 (uPARAP) ADCElerate1
More news about: Adcendo
Apr 13, 2026, 20:00 ET Kelun-Biotech Announces Results from the SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in Gynecologic Oncology Presented at 2026 SGO
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Kelun-Biotech
Apr 12, 2026, 07:15 ET AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026
enrollment of participants most likely to benefit from this FRα‑targeted ADC approach.About ELAHERE®ELAHERE® (mirvetuximab soravtansine-gynx) is a first-in-class antibody-drug conjugate (ADC) comprising a folate receptor alpha-binding antibody, cleavable linker
More news about: AbbVie
Apr 10, 2026, 07:25 ET DualityBio gibt Annahme des Zulassungsantrags für Trastuzumab Pamirtecan zur Behandlung von nicht resezierbarem oder metastasiertem HER2-positivem Brustkrebs bei erwachsenen Patienten durch die chinesische NMPA bekannt
und führenden Biotech-Innovatoren aufgebaut. Als global führendes Unternehmen im ADC-Bereich entwickelt DualityBio neuartige ADCs, darunter bispezifische ADC-Kandidaten, ADC-Kandidaten mit neuartigen Nutzlasten sowie ADC-Kandidaten für Autoimmunerkrankungen.Weitere Informationen finden Sie auf
More news about: DualityBio
Apr 10, 2026, 07:23 ET DualityBio annonce l'acceptation par la NMPA chinoise de la demande d'autorisation de mise sur le marché du trastuzumab pamirtecan pour le traitement du cancer du sein HER2 positif non résécable ou métastatique chez l'adulte
biotechnologiques de premier plan. En tant qu'acteur majeur dans le domaine des ADC, DualityBio développe de nouveaux ADC, notamment des candidates ADC bispécifiques, des candidates ADC à charge utile innovante et des candidates ADC auto-immuns.Pour plus d'informations, veuillez consulter le site
More news about: DualityBio
Apr 10, 2026, 07:00 ET Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026
biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today presented three posters from a real-world analysis supporting the therapeutic potential of targeting mucin 16 (MUC16) with a next-generation ADC for the treatment of ovarian and endometrial cancers at the Society
More news about: Whitehawk Therapeutics, Inc.
Apr 09, 2026, 12:55 ET DualityBio anuncia la aceptación de NMPA de China de su solicitud de licencia para productos biológicos
candidatos a ADC en fase clínica.Además, DualityBio ha establecido colaboraciones estratégicas con multinacionales globales e innovadores biotecnológicos líderes. Como potencia mundial en el campo de los ADC, DualityBio está desarrollando nuevos ADC, incluyendo candidatos a ADC biespecíficos,
More news about: DualityBio
Apr 09, 2026, 12:28 ET Aqaba to Host Landmark Global Marine Sports and Diving Event with Participation from 25 Countries in September 2026
future of the sector.The exhibition is organized by Arabia First for Conferences and Exhibitions, hosted by the Aqaba Development Corporation (ADC), and held in strategic partnership with Fira Barcelona, one of the world's leading exhibition organizers.The event represents a strategic step
More news about: Aqaba Blue Ocean Future in Action
Apr 09, 2026, 08:16 ET DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
strategic collaborations with global MNCs and leading biotech innovators. As a global ADC powerhouse, DualityBio is developing novel ADCs, including bispecific ADC candidates, novel-payload ADC candidates, and autoimmune ADC candidates.For more information, please visit
More news about: DualityBio
Apr 09, 2026, 07:55 ET DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
strategic collaborations with global MNCs and leading biotech innovators. As a global ADC powerhouse, DualityBio is developing novel ADCs, including bispecific ADC candidates, novel-payload ADC candidates, and autoimmune ADC candidates.For more information, please visit
More news about: DualityBio
Apr 09, 2026, 06:20 ET Kelun-Biotech Approved by HKEX to Remove "B" Marker from Stock Code, Representing a New Stage of Development
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Kelun-Biotech
Apr 08, 2026, 09:00 ET Altruist Biologics' Hangzhou Facility Secures First Commercial Manufacturing License
bioreactors, the first and largest of their kind in China. The site will hold a total capacity of 172,000 liters upon completion. It also offers a standalone ADC and AXC bioconjugation facility to support the manufacture of various bioconjugates, including high potency ADCs for clinical and commercial supply in
More news about: Altruist Biologics
Apr 08, 2026, 09:00 ET Altruist Biologics' Hangzhou Facility Secures First Commercial Manufacturing License
bioreactors, the first and largest of their kind in China. The site will hold a total capacity of 172,000 liters upon completion. It also offers a standalone ADC and AXC bioconjugation facility to support the manufacture of various bioconjugates, including high potency ADCs for clinical and commercial supply in
More news about: Altruist Biologics
Apr 07, 2026, 10:30 ET EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
TUB-040, a NaPi2b-directed topoisomerase-I inhibitor (TOPO1i) ADC, is currently in Phase 1b/2 development for platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC). Gilead will also acquire TUB-030, a 5T4 targeted ADC, which has demonstrated promising initial clinical data across various
More news about: EQT
Apr 07, 2026, 10:27 ET EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
TUB-040, a NaPi2b-directed topoisomerase-I inhibitor (TOPO1i) ADC, is currently in Phase 1b/2 development for platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC). Gilead will also acquire TUB-030, a 5T4 targeted ADC, which has demonstrated promising initial clinical data across various
More news about: EQT
Apr 06, 2026, 23:28 ET Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026
established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.
More news about: Akeso, Inc.
Apr 06, 2026, 10:00 ET K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate Demonstrates Tumor-Selective Pharmacokinetics, Extensive Intratumoral Distribution and Superior Efficacy in Non-Clinical Animal Models
Meeting 2026 | Meetings | AACRAbout K-679K-679 is an Antibody Drug-loaded Unimicelle Conjugate (ADUC), a novel type of ADC using Kowa's proprietary micelle technology, currently in nonclinical development. The conjugate combines an anti-EGFR antibody with drug (DM1)-loaded
More news about: Kowa Company Ltd.
Apr 06, 2026, 04:00 ET K-679: Новый унимицеллярный конъюгат, загруженный антителом и лекарственным средством, демонстрирует опухолеселективную фармакокинетику, обширное внутриопухолевое распределение и превосходную эффективность в доклинических моделях на животных
превосходную эффективность в отношении солидных опухолей, экспрессирующих EGFR, по сравнению с обычными конъюгатами антитело-лекарственное средство (ADC). Данные будут представлены на ежегодном собрании Американской ассоциации по исследованию рака (AACR) 2026 года, которое состоится в Сан-Диего, штат
More news about: Kowa Company Ltd.
Apr 06, 2026, 04:00 ET K-679: nový konjugát unimicelov s obsahom protilátok a liečiv vykazuje selektívnu farmakokinetiku pre nádory, rozsiahlu intratumorálnu distribúciu a vynikajúcu účinnosť v neklinických zvieracích modeloch.
konvenčných ADC.V neklinických štúdiách preukázal K-679 farmakokinetiku selektívnu pre nádor, rozsiahlu intratumorálnu distribúciu a zhodné priestorové farmakodynamické účinky v xenotransplantátových modeloch v porovnaní s referenčným konjugátom s obsahom protilátky a liečiva (ADC). K-679 tiež
More news about: Kowa Company Ltd.
Apr 06, 2026, 04:00 ET K-679: Nový konjugát unimicely nesoucí protilátku a léčivo vykazuje nádorově selektivní farmakokinetiku, rozsáhlou intratumorální distribuci a vynikající účinnost v neklinických zvířecích modelech
protilátce (DAR) přibližně 45 molekul DM1 na jednu protilátku, což je výrazně více než u konvenčních ADC.V neklinických studiích prokázal K-679 ve srovnání s referenčním konjugátem protilátky a léčiva (ADC) nádorově selektivní farmakokinetiku, rozsáhlou intratumorální distribuci a shodné prostorové farmakodynamické
More news about: Kowa Company Ltd.
Apr 06, 2026, 04:00 ET El conjugado K-679 demuestra farmacocinética selectiva para tumores
la de los ADC convencionales.En estudios no clínicos, K-679 ha demostrado farmacocinética selectiva para tumores, una amplia distribución intratumoral y efectos farmacodinámicos espaciales concordantes en modelos de xenoinjerto, en comparación con un conjugado anticuerpo-fármaco (ADC) de referencia.
More news about: Kowa Company Ltd.
Apr 06, 2026, 04:00 ET K-679: innowacyjny koniugat przeciwciała i miceli będącej nośnikiem leku wykazuje właściwości farmakokinetyczne umożliwiające selektywne oddziaływanie na guzy nowotworowe, rozległe działanie wewnątrz guza i wysoką skuteczność w nieklinicznych modelach zwierzęcych
działanie wewnątrz guza oraz doskonałą skuteczność w przypadku guzów litych z ekspresją EGFR w porównaniu z konwencjonalnymi koniugatami przeciwciało-lek (ADC - antibody drug conjugate). Dane zostaną przedstawione podczas dorocznej konferencji Amerykańskiego Stowarzyszenia Badań nad Rakiem 2026 (AACR, American
More news about: Kowa Company Ltd.